Applied Clinical Trials-04-01-2014

Examining a region's comparator reimbursement climate to better inform trial expansion decisions.

Industry news focusing on the people and organizations who work in the clinical trials profession.

As pair of initiatives show, the clinical trials community in Europe is working harder to get its message across to its key partner: patients.

The integration of pre-screening all patients for eligibility in oncology studies.

When examining the frequency in use of keywords related to cancer research, some important trends emerge.

The advent of new drugs for tuberculosis is posing some interesting challenges for regulators in Europe.

ISR

Despite guidances and rules advising sponsors to include all demographic groups in clinical trials, many subgroups remain underrepresented.

Half of all drugs in clinical testing are interrupted by in-licensing, co-development, joint venture and M&A arrangements – and they are taking significantly more time to develop.

The prevalence of cardiovascular toxicity associated with oncology drugs has triggered a new clinical discipline that aims to promote safer drugs and better outcomes for cancer patients.

S

Sites: Making a Difference in Cancer Trials Accrual Trial Design: Oncology Trial Comparator Drug Reimbursement Also in this issue: Singular Approach to Combination Trials Risk Sharing and Interrupted Drug Development Cardio-Oncology: A New Clinical Discipline